Rooted in Science. We put the health of your family first.

Key Discoveries in the Therapeutic Application of Cord Blood: Improvement of Motor Function in Children with Cerebral Palsy

WALTHAM, Massachusetts – October 31, 2017 –Research published in Stem Cells Translational Medicine shows encouraging developments related to using a child’s own cord blood to treat childhood brain injury known as cerebral palsy (CP). 

The research from a Phase II clinical trial indicates that patients with CP who were treated with an infusion of an adequate dose of their own cord blood, which had been collected and stored at birth, saw a significant improvement in their motor function. Of the 63 children receiving treatment, those who were given a dose higher than 20 million cells per kilogram showed improvements in motor function measured on a validated scale for assessing motor function in children with CP called the Gross Motor Function Measure (GMFM-66).

“This is the first demonstration of a therapy producing durable improvements in motor function in young children with CP. We are very encouraged by these results. Our research has indicated that autologous cord blood infusions are feasible, safe and easily administered in the outpatient setting,” said Joanne Kurtzberg, MD, Director, Carolinas Cord Blood Bank and Pediatric Blood and Marrow Transplant Program; Chief Scientific Officer, Robertson Clinical and Translational Cell Therapy Program, Duke University, who led the clinical trial. 

The purpose of this Phase II trial was to determine the efficacy of using a child’s own (autologous) cord blood for the treatment of pediatric patients with cerebral palsy. The primary measure of efficacy was a significant change in standardized measure of motor function over what would have been expected at one year without the treatment. Further details can be found here.

“Before our son Patrick’s cord blood treatment, things were so overwhelming for him and our family. Patrick struggled with therapy, school and the normal daily activities you take for granted,” said GiGi and Kevin Rooney, the parents of a child who participated in the study. “Today, after his cord blood treatment, Patrick has great stamina and endurance and the confidence to try new things. Having his cord blood and being in this study has tremendously impacted our lives for the better and we are truly grateful.” 

These findings in children with CP follow the publication in April 2017 of results from a Phase I trial testing the safety of using a child’s own cord blood to treat Autism Spectrum Disorder (ASD) published in Stem Cells Translational Medicine. Duke continues to study the use of cord blood to treat children with Autism Spectrum Disorder in a Phase II Clinical Trial using both autologous and allogeneic cord blood, and recently completed a Phase I study in children with CP who were treated with cord blood from a sibling. 

“For more than 20 years, ViaCord has collaborated on projects to determine the clinical utility of cord blood stem cells. These initial findings mark an exciting development in the potential use of cord blood stem cells for treating Cerebral Palsy, and a significant step in establishing the role of cord blood beyond transplant medicine and into regenerative medicine, including Autism,” said Morey Kraus, Chief Scientific Officer, ViaCord. “We are proud that ViaCord families were able to participate in this historic study by having access to their own cord blood, and we look forward to helping many more families.” 

ViaCord, PerkinElmer’s (NYSE:PKI) cord blood and cord tissue preservation business, has preserved the umbilical cord stem cells of more than 350,000 newborns and released over 350 cord blood units for treatment and clinical research studies. It has released more than 200 cord blood units for use in the treatment of nearly 80 diseases including acute lymphoblastic leukemia and sickle cell disease and more than 150 cord blood units for use in clinical research studies including this study for Cerebral Palsy and Autism Spectrum Disorder. 

Please visit www.viacord.com for more information. Follow ViaCord on Twitter @ViaCord. 

About PerkinElmer 

PerkinElmer is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide are passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. 

### 

Contact:
Elizabeth Tripp
etripp@apcoworldwide.com
646-556-9324

FOR IMMEDIATE RELEASE
September 7, 2017

WALTHAM, Massachusetts – September 7, 2017 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, expanded its Whole Genome Sequencing (WGS) services to families that preserve  their cord blood and cord tissue with ViaCord.   This launch follows the Company’s recent introduction of its clinical WGS services. 

Parents that choose ViaCord, PerkinElmer’s cord blood and cord tissue preservation business, now have the opportunity to benefit from a physician-ordered WGS test of their child’s DNA via a simple saliva test. The test examines a broad range of disease-related genes and provides diagnostic findings contributing to pediatric onset diseases. Additionally, the test reports on pharmacogenetic variants used to optimize certain drug selection. 

“WGS is another great opportunity for families to identify and prepare for important health concerns, positioning themselves to benefit from the fast moving area of personalized medicine,” said Morey Kraus, chief scientific officer, ViaCord. “We have seen tremendous progress using cord blood stem cells to treat disease, and I expect families who make such health conscious decisions to benefit from WGS as well.  Additionally, with the rapid progress we’ve seen with regenerative medicine and gene editing, insights from WGS may be used in the future, in combination with a family’s cord blood and cord tissue, to optimize the design of a treatment plan.  This is a very exciting next new step in advancing personalized medicine.”

ViaCord has preserved the umbilical cord stem cells of more than 350,000 newborns and released over 360 cord blood units for treatment and clinical research studies.  It has released more than 200 cord blood units for use in the treatment of nearly 80 diseases including acute lymphoblastic leukemia and sickle cell disease and more than 150 cord blood units for use in clinical research studies including for Cerebral Palsy and Autism Spectrum Disorder.

About PerkinElmer
PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide is passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us.   The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) the approval of the Brexit Referendum in the United Kingdom; (21) our ability to realize the full value of our intangible assets; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in  our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media Contact:
Brian Willinsky
+1-781-663-5728
brian.willinsky@perkinelmer.com

FOR IMMEDIATE RELEASE
April 5, 2017

WALTHAM, Mass. – April 5, 2017–  Novel research results from Duke University’s Robertson Clinical and Translational Cell Therapy Program published today in the April issue of Stem Cells Translational Medicine indicate promising developments related to using a baby’s own cord blood stem cells to treat Autism Spectrum Disorder (ASD).

Drs. Joanne Kurtzberg, MD, Director, Carolinas Cord Blood Bank and Pediatric Blood and Marrow Transplant Program; Chief Scientific Officer, Robertson Clinical and Translational Cell Therapy Program and Geraldine Dawson, PhD, Professor of Psychiatry and Behavioral Sciences; Professor of Pediatrics and Psychology and Neuroscience; Director, Duke Center for Autism and Brain Development, led the Phase 1 clinical trial. ViaCord, PerkinElmer’s private cord blood and cord tissue preservation business, helped to fund the study and provided nearly one-half of the cord blood units used by the participating families. 

“We are pleased that this study demonstrated the safety of treating children with ASD with their own cord blood,” said Kurtzberg.  “We’re also encouraged that, while small and non-randomized, there were observed improvements in a majority of the children reported by clinicians and parents.  Without the support of ViaCord and later, the Marcus Foundation, the study would not have been possible.  We are now hoping to replicate these preliminary results in a Phase II randomized clinical trial for which enrollment is nearly complete.”

The trial was designed to determine the safety of an intravenous infusion of autologous umbilical cord blood for the treatment of pediatric patients with ASD.  A secondary research endpoint to evaluate the feasibility of outcome measures was based on the change in each child’s socialization and communication abilities and autism symptoms, measured via parent report, direct observation, and clinician judgment. The study also incorporated novel methodologies using eye-tracking that assessed how the child processed social information.  The results indicated that the treatment is safe and preliminarily indicated improvements in symptoms across all domains in the majority of children receiving an adequate cell dose.

“When my son was just a year old, he was overly sensitive to noises like lawn mowers and was not babbling at all,” said Kristina, a mother whose child participated in the study. “But since his treatment at age 3, and in conjunction with therapy, his improvement has been steady and he’s now very social and able to interact independently with his peers, he can communicate more clearly with children and adults, and his sensory problems are gone. With support, he entered a mainstream elementary school program this past fall. We are extremely grateful to have participated in this study, and so happy with his continued improvement, now years after his treatment.”

“For more than 20 years, ViaCord has actively participated in developments to increase the clinical utility of cord blood stem cells.  Over the last few years, cord blood applications have expanded beyond transplant medicine into areas of regenerative medicine like ASD and brain injuries,” said Morey Kraus, Chief Scientific Officer, ViaCord. “I’ve never been more optimistic about the potential of cord blood. It is very gratifying to have collaboration with Drs. Kurtzberg and Dawson at Duke in this ground breaking trial having the potential to transform the lives of thousands of families who have children with ASD.”

Further details on the Phase II trial can be found at:  clinicaltrials.gov/ct2/results?term=NCT02847182

ViaCord has preserved the umbilical cord stem cells of more than 350,000 newborns and released stem cells for the treatment of diseases such as acute lymphoblastic leukemia, thalassemia major, and sickle cell disease. It has also released more than 340 units of cord blood for clinical use, including this ASD study. For over 25 years, cord blood stem cells have been used in transplant medicine and today can be used in the treatment of nearly 80 diseases.  Please visit www.viacord.com for more information. Follow ViaCord on Twitter @ViaCord.

About PerkinElmer

PerkinElmer, Inc., a global leader focused on innovating for a healthier world, provides private cord blood and cord tissue preservation to families through ViaCord, LLC.  PerkinElmer reported revenue of approximately $2.1 billion in 2016, has about 9,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

 ###

Contact:

Elizabeth Tripp
etripp@apcoworldwide.com
646-556-9324

FOR IMMEDIATE RELEASE
June 16, 2014  

Breakthrough Research to Investigate Safety of Cord Blood Stem Cells as Potential Future Treatment Option for Autism Spectrum Disorder

WHAT:  ViaCord, PerkinElmer's family cord blood and tissue preservation business, announced the launch of a phase I clinical trial at Duke University Medical Center to investigate the safety of autologous umbilical cord blood infusion in children with Autism Spectrum Disorder (ASD).

According to a recent report¹ by the Centers for Disease Control and Prevention (CDC), the number of U.S. children with ASD has sharply increased to 1 in 68 -- a 30 percent increase from two years ago, when the CDC estimated that 1 in 88 children had this disorder.

"We are pleased to collaborate with Duke University Medical Center by sponsoring this important study to determine the safety of cord blood for potentially treating this prevalent disorder facing children worldwide," said Morey Kraus, Chief Scientific Officer, ViaCord. "Cord blood has not traditionally been closely evaluated as a possible safe treatment option for ASD. Aligning our efforts with the experts at a leading medical research center underscores our commitment to improving the lives of children and families struggling with ASD."

HOW: The single site Phase 1 safety study includes 20 subjects and is designed to objectively evaluate safety and multiple measures of social behavior and irritability in young children diagnosed with ASD. Children ages 24-72 months of age with a confirmed diagnosis of ASD and a banked autologous unit of umbilical cord blood of adequate size and quality may be eligible to participate.

Researchers will assess the feasibility of various outcome measures to determine which measure(s) can be used as primary and secondary endpoints for a future randomized phase II clinical trial.

"We are excited to conduct this important study in children with Autism Spectrum Disorder. We hope to learn whether cord blood infusions are safe and to define the best tests to use to study the effects of cord blood in future studies", said Joanne Kurtzberg, MD, Director, Carolinas Cord Blood Bank and Pediatric Blood and Marrow Transplant Program, Chief Scientific Officer, Robertson Clinical and Translational Cell Therapy Program, Duke University.

MORE: More information on the Autism clinical trial at Duke University Medical Center is available by contacting cordbloodtherapyinfo@dm.duke.edu or 844-800-2673.

Cord blood is also being used in the Duke Translational Medicine Institute's Cerebral Palsy clinical trial, which has recently completed enrollment. Duke's researchers have accepted numerous cord blood units from ViaCord for this study, which investigates the potential benefits of autologous reinfusion of cord blood stem cells for children with cerebral palsy.

Cord blood stem cells have been used in the treatment of nearly 80 diseases, and more than 30,000 treatments using donor cord blood have been conducted worldwide using cord blood stem cells. ViaCord has released stem cells for the treatment of diseases ranging from acute lymphoblastic leukemia, thalassemia major and sickle cell disease. ViaCord has preserved the umbilical cord stem cells of more than 300,000 newborns.

ViaCord's family cord blood and cord tissue services also offer expectant families the opportunity to bank their baby's umbilical cord blood and tissue for potential medical use by the child or a related family member. Through its Sibling Connection Program, ViaCord also provides the opportunity for expectant parents, who have an eligible child in need of a transplant, to receive cord blood and cord tissue stem collection, processing and five years of storage, at no cost. Please visit www.viacord.com for more information.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

FOR IMMEDIATE RELEASE
December 16, 2013

Cord Blood Registry & ViaCord Praise Introduction of Family Cord Blood Banking Act

Cord Blood Registry (CBR) and ViaCord, a division of PerkinElmer Inc. - two of the largest family cord blood banks in the nation - joined together today to praise U.S. Representatives Aaron Schock (R-IL) and Ron Kind (D-WI) for reintroducing HR 3673, the Family Cord Blood Banking Act.

The bipartisan legislation will ensure that umbilical cord blood banking services are recognized as a qualified medical expense so that the more than one million American families who have already banked their child's umbilical cord blood stem cells, and the millions of families who choose to do so in the future, can use tax-advantaged health dollars for the collection, processing and storage of these life-saving cells.

"As industry leaders, both CBR and Viacord are committed to doing all we can to increase awareness of the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future. We wholly endorse the Family Cord Blood Banking Act to establish cord blood banking as a qualified medical expense, thus helping American families access cord blood banking services through tax-advantaged health accounts," said Geoff Crouse, CEO of CBR.

Umbilical cord blood contains unique stem cells that can be collected immediately following birth from the umbilical cord. These stem cells have been used in more than 30,000 transplants worldwide during the last 25 years in the treatment of nearly 80 diseases in both adults and children. These stem cells also show great promise for regenerative medicine applications; in fact, aside from current treatments for many anemias, leukemia and certain other cancers, FDA-regulated clinical trials are currently underway to study the use of a child's own cord blood stem cells to treat autism, cerebral palsy, traumatic brain injury and pediatric stroke.

"Viacord is excited to join with CBR in supporting this important piece of legislation. The Family Cord Blood Banking Act will make cord blood banking more affordable for American families and provide incentives to ensure that this valuable health resource is never thrown away," said Jim Corbett, President of Diagnostics for PerkinElmer.        

Specifically, the Family Cord Blood Banking Act will allow expectant parents to use tax-free dollars to pay for cord blood banking services through Health Savings Accounts (HSA), Health Reimbursement Accounts (HRA), Flex Spending Accounts (FSA) and the medical expenses tax deduction. Unlike other medical therapies that can be acquired at any time, the very nature of cord blood requires that it be processed and stored before medical use. Consequently, cord blood banking is a medical expense even though the use of these cells may not occur until later. Finally, the Family Cord Blood Banking Act will allow more Americans to recognize the long-term healthcare benefits of having a source of their own genetically unique stem cells stored for future use. 

About Cord Blood Registry

Cord Blood Registry® (CBR®) is the world's largest newborn stem cell company.  Founded in 1992, CBR is entrusted by parents with storing more than 500,000 cord blood and cord tissue units. The company is pioneering FDA-regulated clinical trials through partnerships with leading medical institutions exploring the use of newborn stem cells to treat a variety of serious conditions such as autism, cerebral palsy and traumatic brain injury. For more information, visit www.cordblood.com.

About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. Join the conversation and follow us on twitter at www.twitter.com/perkinelmernews.

# # #

Contacts:

Cord Blood Registry

Brian Plummer

650-635-1420 ext. 255               

bplummer@cordblood.com

Edelman (On behalf of PerkinElmer, Inc.)

Jen Reid 

404-460-8587 

jen.reid@edelman.com

SOURCE Cord Blood Registry and Viacord

FOR IMMEDIATE RELEASE

11/15/07

PerkinElmer Completes Acquisition of ViaCell

Strengthens Commitment to Neonatal, Prenatal and Maternal Health Solutions

WALTHAM, Mass. – PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences, today announced that it has successfully completed its acquisition of ViaCell, Inc., a biotechnology company specializing in the collection and preservation of umbilical cord blood stem cells. The acquisition expands PerkinElmer’s offerings and reach in the neonatal, prenatal and maternal health markets.

ViaCell’s ViaCord^® product offering allows expectant families to preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. The addition of ViaCord and ViaCell’s highly qualified sales and marketing organization provides PerkinElmer with a leading offering in the rapidly growing cord blood banking business, as well as an enhanced ability to reach obstetric professionals and prospective parents. ViaCell customers will continue to benefit from ViaCord’s high-quality cord blood banking offering and expertise, and now will have access to a wider range of neonatal, prenatal and maternal health solutions from PerkinElmer.

“PerkinElmer is committed to protecting the health of mothers and babies from pregnancy through birth and beyond,” said Robert F. Friel, President and Chief Operating Officer, PerkinElmer. “The addition of ViaCell marks another step in our efforts to become a leading provider of innovative prenatal, neonatal and maternal healthcare solutions. We will continue to look for opportunities to build our product portfolio and provide the most comprehensive and accurate assessment of newborn and maternal health to families and their healthcare providers.”

PerkinElmer is the world’s leading provider of newborn screening systems, offering the world’s first and only tandem mass spectrometry (MS/MS) kit cleared by the FDA as an aid to screening for inborn errors of metabolism. The Company continues to drive the advancement of newborn screening with the capability to analyze more than 40 disease markers with a single blood sample. PerkinElmer estimates that every baby screened in the U.S. today is tested using its screening tools, and has helped identify more than 100,000 infants globally who were determined to be at risk for potentially life-threatening diseases.

As part of its rapidly growing offerings for prenatal and maternal health, PerkinElmer currently offers Ultra-Screen^®, a first-trimester prenatal screening protocol designed to provide patient-specific risk assessment for certain chromosomal abnormalities, through its clinical test subsidiary, NTD Laboratories. The Company also holds a global licensing agreement to develop assay kits for the ADAM12 biochemical marker, which has broad potential in maternal health screening for fetal chromosomal abnormalities, and has secured global rights for Placental Protein 13 (PP13), a new maternal serum marker currently under investigation that has shown potential for early detection of pre-eclampsia in low-risk groups.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to our genetic screening business. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. 

# # #

For further information regarding PerkinElmer, please contact:

Investor Relations:

Michael A. Lawless 
PerkinElmer, Inc. 
(781) 663-565

Media Contact:

Michael J. Lorenc

PerkinElmer, Inc.

(781) 663-5701

PerkinElmer, Inc.

940 Winter Street

Waltham, MA 02451 USA

Phone: 781-663-6900

Fax: 781-663-5985

www.perkinelmer.com

• Study Seeks to Discover Method of Treating More Adults Using Cord Blood Stem Cells
• M. D. Anderson Clinical Research Trial Explores Co-Culture Expansion Technology

FOR IMMEDIATE RELEASE

9/18/07

Cambridge, MA (September 18, 2007) ViaCell, Inc. (Nasdaq: VIAC) today announced that it is expanding its ViaCord Processing Facility (VPL), the Company’s state-of-the-art cord blood processing and storage facility. The expansion of VPL will support anticipated future demand of ViaCord®, its product offering for the preservation of cord blood. ViaCell will conduct renovations in the newly leased space in order to meet its planned cord blood processing and storage needs for the coming years. The expansion is expected to be completed in the first quarter of 2008.

“The expansion of our cord blood processing facility will more than double our storage capacity and positions us to meet increasing demand for ViaCord,” said Jim Corbett, President of ViaCell Reproductive Health.

ViaCord has been successfully processing cord blood since 1995 and processing cord blood at VPL since 2002. This facility is AABB accredited and incorporates industry-leading standards, including a closed processing system, storage of cord blood with multiple attached segments, use of the only-FDA cleared process automation equipment and laboratory testing performed in accordance with Clinical Laboratory Improvement Amendments (CLIA) regulations.

About Umbilical Cord Blood

Umbilical cord blood is a valuable, non-controversial source of stem cells with proven therapeutic effect in treating over 40 diseases. These diseases include various forms of cancer, such as Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s lymphoma; certain bone marrow failure syndromes, such as severe aplastic anemia and Diamond Blackfan anemia; certain blood disorders such as sickle cell anemia, thalassemia; and other genetic disorders. Over 8,000 cord blood transplants have been performed worldwide. Studies have shown that umbilical cord blood transplants from a family member, rather than from a non-relative, have a significantly higher survival rate than transplants from an unrelated donor.

About ViaCord

ViaCord allows expectant families the opportunity to preserve their baby’s umbilical cord blood for potential medical use by the child or a related family member. The child’s cord blood is collected at the time of birth in the only FDA-approved cord blood collection bag suitable for use in a sterile field. To date, ViaCord has preserved over 130,000 newborn’s umbilical cord blood. Additional information about ViaCord is available online at http://www.viacord.com.

About ViaCell

ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. The Company is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, and diabetes. Additional information about ViaCell is available online at http://www.viacellinc.com.

Risks of Forward-Looking Statements

This press release contains forward-looking statements regarding the Company's expectations with respect to its ViaCord product offering and timing for completion of the expansion of ViaCord Processing Laboratory. These statements are based on management's current expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the Company's current expectations. For example, the Company's expectations with respect to ViaCord may be negatively affected by the impact of competition in the umbilical cord preservation industry, any changes in market acceptance for family cord blood banking, any slowing of growth of the family cord blood banking market, the impact of any potential adverse outcome in pending patent infringement litigation related to the cord blood preservation business, any further impact of a third party's dispute with Mothers Work related to the rights granted to the Company, including if a court were to vacate the arbitrator's decision, and any unexpected material issues, delays or failures in the collection, processing or storage of umbilical cord blood by the Company or others in the industry. In addition, the Company’s expectations for the completion of the expansion may be impacted by, among other things, unexpected delays in planned construction work in the new space and in obtaining the requisite permits and other approvals necessary to complete the construction work and begin operations in the new space. For more detailed information on the risks and uncertainties associated with these forward-looking statements and the Company's other activities, see the periodic reports filed by the Company with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

ViaCell® and ViaCord® are registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.

###

FOR IMMEDIATE RELEASE

7/9/07

Court Upholds Finding of Non-Infringement and Invalidates Patents

Cambridge, MA (July 9, 2007)  ViaCell, Inc. (Nasdaq: VIAC) today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in favor of ViaCell in a patent infringement suit brought against the Company and other defendants by PharmaStem Therapeutics, Inc. The Federal Circuit upheld an earlier decision by the U.S. District Court for the District of Delaware that ViaCell, through its marketing of ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use, does not infringe PharmaStem’s U.S. Patent No. 5,192,553 (‘553) and U.S. Patent No. 5,004,681 (‘681), which relate to certain aspects of collection, cryopreservation, storage and use of hematopoietic stem cells from umbilical cord blood. The court also found the ‘553 and the ‘681 patents invalid based on prior art.

“We are extremely pleased with this ruling and believe this is a major step toward bringing closure to the suits brought against us,” said Marc D. Beer, President and Chief Executive Officer of ViaCell.

A copy of the Federal Circuit’s decision is available online at http://www.fedcir.gov.

Background on Litigation

In 2002, PharmaStem brought suit against ViaCell and several other defendants alleging infringement of the ‘553 and ‘681 patents. The patents relate to certain aspects of the collection, cryopreservation, storage, and use of hematopoietic stem cells from umbilical cord blood. In 2004, a District Court judge, in overturning a previous jury verdict against ViaCell and the other defendants in this case, found that PharmaStem had failed to prove infringement. PharmaStem appealed the decision. In April 2006, the U.S. Court of Appeals for the Federal Circuit heard oral argument in the appeal. In 2004, PharmaStem brought a second suit against ViaCell and the other defendants alleging infringement of U.S. Patent Nos. 6,461,645 and 6,569,427. These patents have similar claims to the ‘553 and ‘681 patents. The second case has been stayed pending decisions from the Federal Circuit on the appeal and re-examinations of the patents by the United States Patent and Trademark Office.

About ViaCell

ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses ofumbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility. For more information about ViaCell, visit our website at http://www.viacellinc.com.

- more -

This press release contains forward-looking statements regarding the PharmaStem litigation. Such statements are based on management's current beliefs and expectations. There are a number of risks and uncertainties that could cause actual results to differ materially from management's current beliefs and expectations. The second case brought by PharmaStem based on the ‘645 and ‘427 patents may continue. PharmaStem may seek to appeal the decision of the U.S. Court of Appeals. In such an event, the decision of the U.S. Court of Appeals may be overturned or the case may be remanded to the District Court. We may ultimately be found to infringe valid claims of the PharmaStem patents, in which case we could have a significant damages award entered against us or could face an injunction which could prohibit us from further engaging in the umbilical cord stem cell business absent a license from PharmaStem. We may also incur significant additional legal fees and expenses in connection with this litigation. For more information on the risks and uncertainties associated with this litigation or with the Company and its products and programs, see the factors set forth under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2007, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.

ViaCell® and ViaCord® are registered trademarks of ViaCell, Inc.

###

FOR IMMEDIATE RELEASE

6/13/07

Represents Most Related Cord Blood Transplant Experience

Cambridge, MA and Oakland, CA (June 13, 2007) ViaCord®, the umbilical cord blood preservation division of ViaCell, Inc. (Nasdaq: VIAC), and Children’s Hospital Oakland Research Institute (CHORI) today announced that they have achieved their 100th umbilical cord blood transplant. The 100th transplant was a sibling transplant to treat Severe Combined Immunodeficiency (SCID), commonly known as “bubble boy” disease. This historic milestone includes transplants through cord blood collected, preserved and stored with ViaCord and transplants using cord blood stored through CHORI’s Sibling Donor Cord Blood Program.

In 2006, ViaCell and CHORI combined their efforts in the area of directed transplants for sibling donor umbilical cord blood to form the Sibling Connection Program. This program provides ViaCord’s comprehensive cord blood collection, processing and five years of storage at no cost to families who have a child in need of a transplant and meet the other requirements of the program.

ViaCord and CHORI have the most related cord blood transplant experience. As the leading provider of related cord blood for directed transplantation, ViaCord and CHORI offer transplant physicians and families confidence the cells are processed and stored in a high quality manner at ViaCord’s state-of-the-art cord blood processing laboratory.

“ViaCord stored our younger son’s umbilical cord blood which was later used to treat his brother for sickle cell anemia,” said Ms. Tammy Witherspoon, mother of two in McComb, Mississippi. “After many years of suffering, our older son is now cured of the disease. We are so grateful for this medical advance and urge families to learn more about the potential of umbilical cord blood.”

“The therapeutic effect cord blood has in treating a wide range of diseases supports the need to educate all birthing families about cord blood preservation so they can adequately consider this unique opportunity,” said Brent N. Davidson, MD. Service Chief, Women’s Services, Henry Ford Hospital, West Bloomfield, Michigan. “Moreover, it is important that families understand the clinical advantage of using cord blood stem cells from a related source should they need the preserved cord blood for a future transplant.”

The majority of the ViaCord and CHORI transplants were used to treat siblings for a variety of diseases, including various types of leukemia, Fanconi anemia, sickle cell anemia, and thalassemia, among others. Additionally, several autologous transplants (transplants using the child’s own cord blood) were performed to treat diseases such as severe aplastic anemia and neuroblastoma.

In February 2007, Dr. Mark Walters, Director of the Blood & Marrow Transplant Program at Children’s Hospital & Research Center Oakland and Medical Director of ViaCord’s cord blood processing laboratory, presented findings that related umbilical cord blood units are an effective graft source for treatment in a variety of diseases requiring transplantation. As presented at the American Society of Blood and Marrow Transplantation Meeting, transplant outcomes from units processed and stored through CHORI’s Sibling Donor Cord Blood Program compared favorably with bone marrow transplantation from sibling donors. In 60 patients evaluated, the median time to neutrophil recovery was 22 days. The overall survival at one year was 80%. Acute graft-versus-host-disease, or GVHD (greater than Grade 1), was observed in 25% of allogeneic recipients and only 4% had chronic GVHD. In contrast, 41% of recipients who receive unrelated transplants develop acute GVHD and 25% develop chronic GVHD. ViaCord expects to publish its updated transplant findings at future medical meetings.

About Umbilical Cord Blood

Umbilical cord blood is a valuable, non-controversial source of stem cells with proven therapeutic effect in treating over 40 diseases. These diseases include cancers such as Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s lymphoma, certain bone marrow failure syndromes such as severe aplastic anemia and Diamond Blackfan anemia, certain blood disorders such as sickle cell anemia, thalassemia and other genetic disorders. Over 8,000 cord blood transplants have been performed worldwide. Studies have shown that umbilical cord blood transplants from a family member, rather than from a non-relative, have a significantly higher survival rate than transplants from an unrelated donor.

About ViaCord

ViaCord allows expectant families the opportunity to preserve their baby’s umbilical cord blood for potential medical use by the child or a related family member. The child’s cord blood is collected at the time of birth in the only FDA-approved cord blood collection bag suitable for use in a sterile field. To date, over 115,000 families have preserved their children’s umbilical cord blood through ViaCord. The ViaCord Processing Laboratory, located in Hebron, Kentucky, is an AABB accredited cord blood facility. Additional information about ViaCord is available online at http://www.viacord.com.

Research at Children’s Hospital & Research Center Oakland, CA

Research efforts at Children’s Hospital & Research Center Oakland are coordinated through Children’s Hospital Oakland Research Institute (CHORI). Children’s Hospital Oakland is Northern California’s only freestanding and independent children’s hospital. CHORI’s internationally renowned biomedical research facility brings together seven centers of excellence that are devoted to clinical and basic science research to treat and prevent disease. CHORI has approximately 300 investigators and an annual budget of more than $47 million, primarily supplied by National Institutes of Health grants. The institute is a leader in translational research, bringing bench discoveries to bedside applications. These include providing cures for blood diseases, developing new vaccines for infectious diseases, and discovering new treatment protocols for previously fatal or debilitating conditions such as cancers, sickle cell disease, AIDS/HIV, pediatric obesity, hemophilia and cystic fibrosis.

About ViaCell

ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility. For more information about ViaCell, visit our website at http://www.viacellinc.com.

ViaCell® and ViaCord® are federally registered trademarks of ViaCell, Inc.

###

PerkinElmer's ViaCord® Cord Blood Banking Business Collaborates with Miracle Babies to Improve Collection of Stem Cells from Premature Births for Potential Therapeutic Use

WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced today that its family cord blood banking business, ViaCord®, will now offer families the ability to extract stem cells from the tissue surrounding the umbilical cord vessels, a very rich source of mesenchymal stem cells (MSCs). 

This new capability is exclusive to ViaCord, the only cord blood banking service with patent rights to expand MSCs from cord tissue as well as extract and expand MSCs from the tissue around the cord vessels. This proprietary service will be offered, as part of the current cord tissue stem cell service offering, to expectant parents through an exclusive licensing agreement with Tissue Regeneration Therapeutics (TRT). 

"The agreement between ViaCord and TRT provides our customers with access to a very rich source of MSCs from umbilical cord tissue, increasing their chances of potential success and benefit from possible therapeutic applications. In addition, the agreement will further distinguish ViaCord's portfolio of offerings in the area of cord tissue banking," said Morey Kraus, chief scientific officer for ViaCord. "ViaCord will also collaborate with TRT on a research initiative investigating the therapeutic benefits and anti-inflammatory properties of this rich source of MSCs. This research is intended to achieve results that may guide clinical studies of stem cell applications for joint diseases, including rheumatoid arthritis and osteoarthritis, as well as autoinflammatory diseases, such as irritable bowel syndrome." 

"ViaCord has established a lead position in the study and identification of new uses for stem cell treatments within the clinical setting, and is an ideal complement to the robust scientific foundation that we, at TRT, have built in the MSC field," said John E. Davies, president and chief executive officer of Tissue Regeneration Therapeutics. "We are delighted that ViaCord customers will benefit from this exclusive licensing agreement and our collaborative research to advance therapeutic uses of MSCs." 

The extraction is enabled through TRT's human umbilical cord perivascular cell (HUCPVC) technology, allowing ViaCord to extract the stem cells found around the umbilical cord vessels. This process creates access to perivascular MSCs, a highly potent type of stem cell, which offers a potentially significant medical advantage. ViaCord's added ability to expand the stem cells can also increase the available supply by tenfold or greater, providing more stem cells for more potential treatments. Banking newborn cord tissue stem cells in addition to cord blood stem cells provides a greater number and variety of cells, increasing chances of potential success and benefit from possible therapeutic applications. 

The partnership with TRT augments the proprietary position that was initiated by the agreement between ViaCord and AuxoCell Laboratories, Inc., which was entered into in March 2011. The combined agreements provide ViaCord customers with exclusive access to both MSC extraction and expansion technologies. 

ViaCord family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood for potential medical use by the child or a related family member. To date, ViaCord has preserved the umbilical cord blood of more than 250,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today there are nearly 80 diseases treatable with cord blood stem cells, including cancers, certain blood disorders and immunodeficiencies. 

About Tissue Regeneration Therapeutics (TRT) 

TRT is a progressive biotechnology Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology, which represents the world's richest source of mesenchymal stem cells (MSCs). TRT is the first company in the world to have issued and allowed patents in both the USA and Europe for extraction of these unique cells from umbilical cord tissue. TRT provides license opportunities to collaborating partner companies in the regenerative therapeutics industry, including Family Banking. In June 2006, TRT exclusively licensed rights for the Canadian market to CReATe Cord Blood Bank in Toronto, who market HUCPVCs as PeristemTM, making both TRT and CreATe leaders in the worldwide stem cell community. TRT's preclinical and clinical development programs are designed to develop therapies that address important health care issues of today. Additional information is available at www.verypowerfulbiology.com. 

About PerkinElmer, Inc. 

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. 

Additional information is available through 1-877-PKINYSE, or at www.perkinelmer.com. Edelman (On behalf of PerkinElmer, Inc.) 
Amanda L. Connolly, 404-832-6785
amanda.connolly@edelman.com

Source: PerkinElmer, Inc. News Provided by Acquire Media

PerkinElmer’s ViaCord® Family Cord Blood Banking Business Announces First and Only Service to Bank Stem Cells Harvested from Umbilical Cord Tissue Addition of cord tissue stem cell banking services expands patient access to potential therapeutic benefit through more volume and variety of stem cells

WALTHAM, MA – PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that its family cord blood banking business, ViaCord®, will now offer expectant parents umbilical cord tissue stem cell banking services. This latest addition to the ViaCord portfolio complements its cord blood banking service. Umbilical cord tissue is a rich source of mesenchymal stem cells (MSCs). Banking newborn cord tissue stem cells in addition to cord blood stem cells provides a greater number and variety of cells, so patients may increase their chances of potential success and benefit from possible therapeutic applications. Results from more than 50 preclinical studies involving MSCs extracted from cord tissue have been published, underscoring the potential treatment value of MSCs to the scientific and medical community. Published research has found that tissue-derived stem cells have been shown to offer potential treatment of disorders such as Parkinson’s, stroke, type1 diabetes and sports injuries. The new services are enabled through an exclusive licensing agreement with AuxoCell Laboratories, Inc., a leading stem cell therapeutic and regenerative medicine company. Under the terms of the license agreement, ViaCord’s customers are granted exclusive family banking access to Auxocell’s patent for expanding MSCs derived from umbilical cord tissue. Additionally, ViaCord uses Auxocell’s validated technology for processing and cryopreserving MSCs from umbilical cord tissue. "Researchers in a preclinical study, presented by AuxoCell, at the October 2010 meeting of the International Placenta Stem Cell Society, found that combining the stem cells from umbilical cord tissue with stem cells from cord blood results in improved engraftment – up to a six-times increase over cord blood alone," said Morey Kraus, ViaCord’s chief scientific officer. "ViaCord is excited to offer another source of stem cells to our customers. In addition, our relationship with Auxocell allows us to provide our family banking customers with even greater confidence through deploying a validated method for processing these cells and exclusive access to expanding these cells." ViaCord family cord blood banking services currently offers expectant families the opportunity to preserve their baby’s umbilical cord blood for potential medical use by the child or a related family member. To date, ViaCord has preserved the umbilical cord blood of more than 250,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi’s anemia. Today there are nearly 80 diseases treatable with cord blood stem cells, including cancers, certain blood disorders and immunodeficiencies. About PerkinElmer, Inc. PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. # # # Media Contact: Amanda L. Connolly Edelman (On behalf of PerkinElmer, Inc.) Phone: (404) 832-6785 Email: amanda.connolly@edelman.com

FOR IMMEDIATE RELEASE

10/12/07

WALTHAM and CAMBRIDGE, Mass. (October 12, 2007) – On October 12, 2007, Victor Acquisition Corp., an indirect wholly owned subsidiary of PerkinElmer, Inc. (NYSE: PKI), commenced a tender offer to acquire all outstanding shares of common stock of ViaCell, Inc. (Nasdaq: VIAC), at a price of $7.25 per share, in cash, pursuant to a previously announced Agreement and Plan of Merger among PerkinElmer, Inc., Victor Acquisition Corp. and ViaCell, Inc., dated October 1, 2007.

Victor Acquisition Corp.’s obligation to accept for payment and pay for shares of ViaCell common stock tendered in the offer is subject to customary conditions, including, among other things:at least a majority of the outstanding shares of ViaCell common stock on a fully diluted basis shall have been validly tendered in accordance with the terms of the offer and not properly withdrawn; and,

the expiration or termination of applicable waiting periods under the United States Hart-Scott-Rodino Antitrust Improvements Act. The tender offer and any withdrawal rights to which ViaCell’s stockholders may be entitled will expire at 12:00 midnight, New York City time, at the end of November 8, 2007, unless the offer is extended.

The complete terms and conditions of the tender offer are set forth in the Offer to Purchase, Letter of Transmittal and other related materials filed by PerkinElmer with the SEC on October 12, 2007. ViaCell filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC on October 12, 2007, relating to the tender offer. Copies of the Offer to Purchase, Letter of Transmittal and other related materials are available free of charge from Georgeson, Inc., the Information Agent for the tender offer, toll-free at (888) 821-2250 (banks and brokers at (212) 440-9800), or Merrill Lynch & Co., the Dealer Manager for the tender offer, at (877) 653-2948, toll-free. Deutsche Bank Trust Company Americas is acting as Depositary for the tender offer.

Securities Law Disclosure

This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities. The solicitation and the offer to buy shares of ViaCell common stock are being made only pursuant to the Offer to Purchase, Letter of Transmittal and related materials that PerkinElmer, Inc. and Victor Acquisition Corp. have filed with the SEC on a Tender Offer Statement on Schedule TO on October 12, 2007. ViaCell also has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer on October 12, 2007. ViaCell stockholders and other investors should read these materials carefully because they contain important information, including the terms and conditions of the offer. ViaCell stockholders and other investors may obtain copies of these materials without charge from the SEC through the SEC’s Web site at www.sec.gov, from Georgeson, Inc., the information agent for the offer, toll-free at (888) 821-2250 (banks and brokers at (212) 440-9800), from Merrill Lynch & Co., the Dealer Manager for the tender offer, at (877) 653-2948, toll-free, from PerkinElmer by directing a request to PerkinElmer, 940 Winter Street, Waltham, Massachusetts 02451, Attention: Michael A. Lawless, Vice President, Investor Relations or from ViaCell, Inc., 245 First Street, Cambridge, Massachusetts, 02142, Attention: Justine Koenigsberg, Senior Director, Corporate Communications. Stockholders and other investors are urged to read carefully those materials prior to making any decisions with respect to the offer.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the proposed transaction between PerkinElmer and ViaCell, the expected timetable for completing the proposed transaction, and any other statements about PerkinElmer or ViaCell managements’ future expectations, beliefs, goals, plans or prospects constitute forward-looking statements. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the possibility that certain closing conditions to the transaction will not be met, the ability to consummate the transaction, the ability of PerkinElmer to successfully integrate ViaCell’s operations and employees; the ability to realize anticipated synergies and cost savings; and the other factors described in PerkinElmer’s Annual Report on Form 10-K for the year ended December 31, 2006, and in ViaCell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, each of which has been filed with the SEC. Except as otherwise required by law, PerkinElmer and ViaCell disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. PerkinElmer, Inc. reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

About ViaCell

ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. ViaCell markets ViaCord, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell's pipeline is focused in the areas of cancer, cardiac disease, and diabetes. Additional information about ViaCell is available online at http://www.viacellinc.com. Additional information about ViaCord is also available at http://www.viacord.com.

# # #

For further information:

PerkinElmer Investor Contact: PerkinElmer Media Contact:

Michael A. Lawless Kevin J. Lorenc

(781) 663-5659 (781) 663-5701

PerkinElmer, Inc.

940 Winter Street

Waltham, MA 02451 USA

Phone: 781-663-6900

Fax: 781-663-5985

www.perkinelmer.com

FOR IMMEDIATE RELEASE
March 26, 2013

ViaCord Releases 250th Cord Blood Stem Cell Unit
PerkinElmer's Family Cord Blood and Tissue Preservation Business Reaches Significant Milestone

ViaCord, PerkinElmer's family cord blood and tissue preservation business, announced today the release of its 250th umbilical cord blood stem cell unit for use in medical treatments and clinical trials. For nearly 20 years, ViaCord has released life-saving stem cells for disease therapies using a proven method of processing and cryopreserving cord blood. To date, ViaCord has released more units for use in medical treatments and clinical trials than any other family bank.

"Reaching this milestone is a testament to our dedication to improving the quality of life for families," said Morey Kraus, Chief Scientific Officer, ViaCord. "The benefits of cord blood banking are constantly evolving as research, some of which ViaCord has been instrumental in supporting, continues to expand the number of diseases treated. We are excited to continue to assist families who have chosen to bank their newborns' stem cells."

Cord blood stem cells have been used in the treatment of nearly 80 diseases, and more than 30,000 treatments have been conducted worldwide using cord blood stem cells. ViaCord has released stem cells for the treatment of diseases ranging from acute lymphoblastic leukemia, thalassemia major and sickle cell disease. ViaCord's 250th unit was used to treat a patient currently enrolled in the Duke Translational Medicine Institute's Cerebral Palsy Autologous Cord Blood clinical trial conducted at Duke University Medical Center. In this clinical trial, researchers are investigating the potential benefits of autologous reinfusion of cord blood stem cells for children with cerebral palsy.

ViaCord has preserved the umbilical cord stem cells of more than 300,000 newborns. ViaCord's family cord blood and cord tissue services currently offer expectant families the opportunity to bank their baby's umbilical cord blood and tissue for potential medical use by the child or a related family member. Through its Sibling Connection Program, ViaCord also provides the opportunity for expectant parents, who have an eligible child in need of a transplant, to receive cord blood and cord tissue stem collection, processing and five years of storage, at no cost. Please visit www.viacord.com for more information.

About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

# # #

Media Contact:
Jen Reid Edelman (On behalf of PerkinElmer, Inc.)
Phone: (404) 460-8587
Email: jen.reid@edelman.com

FOR IMMEDIATE RELEASE

3/16/06

Atlanta, GA, March 13, 2006  ViaCell, Inc. (Nasdaq: VIAC) announced today preclinical findings evaluating Unrestricted Somatic Stem Cells (USSCs), pluripotent stem cells cultivated from human cord blood, in a small animal model of myocardial infarction. In the study USSCs showed a dose-dependent response and result in functional recovery in an animal model of acute myocardial infarction four weeks post transplantation. These findings were presented today by Dr. Hiroto Iwasaki of Kobe Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology in Isehara, Japan at the American College of Cardiology 55th Annual Scientific Session being held in Atlanta, Georgia.

“These data are very exciting as we’ve seen few examples of a dose-dependent effect of stem cells demonstrated in the cardiac field thus far. While further research is needed, we also demonstrated USSCs differentiate into both endothelial and cardiomyocytes,” said Dr. Takayuki Asahara of Kobe Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology. “Through our work with ViaCell evaluating their proprietary USSCs, we are encouraged about the potential these cells may have to regenerate damaged heart tissue.”

The primary goal of this study was to determine if USSCs would lead to functional improvement after acute myocardial infarction in a small animal model. USSCs were implanted 20 minutes after an acute myocardial infarction was induced by ligating one of the coronary arteries. Key research findings showed engraftment of USSCs in the infarct region and a dose-dependent improvement of heart function conferred by USSCs whereby human skin fibroblasts did not induce any improvement.

“We are encouraged with these research findings and intend to advance this program further in preclinical testing to determine optimal dosing, delivery, and targeting of USSCs as a treatment for cardiac disease. With over 800,000 annual cases of patients surviving a myocardial infarction and 5 million people suffering from chronic heart failure and no proven therapy to repair or regenerate the heart, we believe our USSC program is an important initiative,” said Stephan Wnendt, Ph.D., Senior Vice President of Research and Development at ViaCell.

If the preclinical data support further development, ViaCell expects to file an Investigational New Drug Application (IND) to commence human clinical trials of its USSCs in the cardiac area in late 2006 or early 2007.

Unrestricted somatic stem cells are a pluripotent source of stem cells cultivated from human cord blood mononuclear cells. These cells have the ability to differentiate into many cell types including endothelial cells, fat, bone, cartilage and neuronal cells under specified in vitro culture conditions. Preclinical evidence suggests USSCs can differentiate in vivo in many tissue types as shown by distribution and function of human cells in the liver, bone, bone marrow, brain and heart of transplanted animals. The company believes USSCs may have potential in a number of indications.

Acute myocardial infarction (AMI), or heart attack, occurs when the blood supply to part of the heart muscle is severely reduced or stopped. This occurs when one of the heart's arteries is blocked by an obstruction, such as a blood clot that has formed or plaque formed by arteriosclerosis. If the blood supply is cut off drastically or for a long time, heart muscle cells suffer irreversible injury and die. According to a study by the National Heart, Lung and Blood Institute, there are approximately 1.2 million cases of myocardial infarction each year in the United States, with a fatal outcome in about 42% of cases. Many patients who survive develop a chronic form of heart disease called congestive heart failure (CHF) which is associated with a progressive deterioration of the heart muscle. According to the National Heart, Lung and Blood Institute, approximately 5 million patients suffer from CHF in the United States.

About ViaCell ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell’s Reproductive Health Business Unit commercializes ViaCord®, a product that offers expecting families the option of preserving their baby’s umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore.

This press release contains forward-looking statements regarding the Company’s plans for development of its USSC product candidate, including the timing as to a possible IND filing, and the Company’s views as to the potential for USSCs in the cardiac area and in other indications. Such statements are based on management's current beliefs and expectations. Drug development involves a high degree of risk. There are a number of risks and uncertainties that could cause actual results to differ materially from management’s current beliefs and expectations. The Company’s USSC product candidate is at an early stage of development and has not completed preclinical testing or been tested in humans. Promising results in small animal studies may not be indicative of results that may be obtained in larger animal studies or in humans. Preclinical studies have yielded and may continue in the future to yield inconsistent results. We may not be able to find a way to successfully deliver and target cells to the damaged regions of the heart for trans-vascular delivery or other commercially viable route of administration. There is no assurance that we will be able to show effect in further animal models or that data will support filing the IND and starting clinical trials. Even if we are able to begin clinical trials, there is no assurance that we will be able to show that USSCs are safe and effective in the treatment of cardiac disease. We may encounter technical, regulatory, safety, manufacturing, delivery or intellectual property-related hurdles or issues as we develop this product candidate. For more information on the risks and uncertainties associated with the Company and its products and programs, see the factors set forth under the heading “Risk Factors That May Affect Results” in the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2005, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.

ViaCell® and ViaCord® are registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.

ViaCell® and ViaCord® are federally registered trademarks of ViaCell, Inc.

###